Results 141 to 150 of about 54,372 (282)

Abatacept in difficult-to-treat juvenile idiopathic arthritis

, 2009
Jasmin B Kuemmerle-Deschner1, SM Benseler21Pediatric Rheumatology Clinics, Dept of Pediatrics, University Hospital Tübingen, Germany; 2Dept of Pediatric Rheumatology, The Hospital for Sick Children, Toronto, CanadaAbstract: Juvenile idiopathic ...
SM Benseler, Jasmin B Kuemmerle-Deschner
core  

Single‐Cell RNA Sequencing Informs Precision Targeting of Monogenic Lupus Associated With IKZF1 Haploinsufficiency

Arthritis &Rheumatology, Volume 78, Issue 6, Page 1231-1244, June 2026.
Objective This study aimed to investigate the mechanisms of immune dysregulation in a pediatric patient with monogenic lupus driven by IKZF1 haploinsufficiency. Methods Peripheral immune cells from a patient with IKZF1 haploinsufficiency, patients with lupus with no currently known genetic mutations, and healthy controls were analyzed using single‐cell
Qi Zheng, Yejun Tan, Zhaoling Wang, Yanjie Qian, Qian Ma, Danping Shen, Meiping Lu   +6 more
wiley   +1 more source

Interleukin‐18 Levels Are Associated With Disease Course in Patients With Still Disease Treated With Interleukin‐1 Inhibitors

Arthritis &Rheumatology, Volume 78, Issue 6, Page 1327-1338, June 2026.
Objective To evaluate the prognostic utility of circulating interleukin‐18 (IL‐18) levels in predicting disease activity, macrophage activation syndrome (MAS), and disease course in patients with Still disease (SD) receiving first‐line IL‐1 inhibitors (IL‐1i).
Matteo Trevisan, Manuela Pardeo, Ivan Caiello, Claudia Bracaglia, Arianna De Matteis, Valentina Matteo, Elena Loricchio, Fabrizio De Benedetti, Giusi Prencipe   +8 more
wiley   +1 more source

Juvenile Idiopathic Arthritis [PDF]

Deutsches Ärzteblatt international, 2020
openaire   +2 more sources

Acute Disseminated Encephalomyelitis Presenting as Fever of Unknown Origin in a 4‐Year‐Old Boy: A Case Report

Clinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT A 4‐year‐old boy presented with prolonged fever of unknown origin and systemic inflammation without early neurological signs. MRI revealed multifocal demyelination, and MOG antibodies were positive. He was diagnosed with ADEM and treated with steroids and IVIg, but relapsed twice, consistent with multiphasic disseminated encephalomyelitis ...
Pedro Pau
wiley   +1 more source

Sociodemographic and Visual Outcomes of Juvenile Idiopathic Arthritis Uveitis: IRIS® Registry Study

Oliver Davidson,1,2 Anand E Rajesh,1,2 Marian Blazes,1,2 Ashley Batchelor,1,2 Aaron Y Lee,1,2 Cecilia S Lee,1,2,* Laura C Huang1,3,* On behalf of the IRIS® Registry Analytic Center Consortium1Department of Ophthalmology, University of Washington,
Lee AY, Blazes M, Lee CS, Rajesh AE, Davidson O, Huang LC, Batchelor A   +6 more
core  

High-resolution ultrasound in the early detection and follow-up of TMJ symptoms and signs in Juvenile Idiopathic Arthritis

, 2016
Aim: Temporomandibular joint (TMJ) arthritis is common in children with juvenile idiopathic arthritis (JIA) but often clinically asymptomatic. Clinical signs or symptoms of TMJ dysfunction are not always predictors of bony destruction.
E. Dzsida, P. Cressoni, R. Soldo, C. Bellintani, U. Garagiola, I. Borzani   +5 more
core  

Tacrolimus as Single‐Agent Immunotherapy for Adult‐Onset Myasthenia Gravis: Remission, Relapse, and Safety

CNS Neuroscience &Therapeutics, Volume 32, Issue 6, June 2026.
Tacrolimus monotherapy yields high remission in adult‐onset MG, especially in new‐onset or younger patients. Relapse is linked to low tacrolimus concentration and rapid tapering. Hyperglycemia was the most common ADR. Long‐term use may increase cancer risk.
Zhangyan Geng, Yuting Jiang, Nairong Xie, Wenjia Zhu, Hai Chen, Yaye Wang, Haoran Liu, Qinyao Liu, Congwen Lv, Yu Qian, Yan Lu, Li Di, Min Wang, Min Xu, Xinmei Wen, Bingchuan Xie, Yuwei Da   +16 more
wiley   +1 more source

Physical activity and quality of life of children and adolescents with juvenile idiopathic arthritis, juvenile systemic lupus erythematosus and juvenile dermatomyositis during the COVID-19 pandemic. [PDF]

J Pediatr (Rio J)
Soares R, Silva FC, Fernandez JD, Fraga MM, Terreri MT, Len CA.   +5 more
europepmc   +1 more source

Serious Infection in Crohn's Disease Patients Treated With Ustekinumab: US Food and Drug Administration Active Postmarket Risk Identification and Analysis in the Sentinel Initiative

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1514-1521, June 2026.
The U.S. Food and Drug Administration (FDA) used an Active Postmarket Risk Identification and Analysis (ARIA) system to address a safety issue (serious infection) identified during clinical review of an application to market ustekinumab as a treatment for Crohn's disease (CD). FDA used an active‐comparator new‐user cohort design, data from six Sentinel
Joel L. Weissfeld, Geetha S. Iyer, Suna C. Seo, Andrew Giffin, Andrew L. Simon, Sheryl A. Kluberg, Emma R. Hoffman, Jamal T. Jones, Sarah K. Dutcher, Joyce A. Korvick   +9 more
wiley   +1 more source